AZD7798
Sponsors
AstraZeneca AB, AstraZeneca
Conditions
Crohn DiseaseCrohn's DiseaseCrohns DiseaseCrohn’s Disease and an IleostomyHealthy SubjectsModerate to Severe Crohn's Disease
Phase 1
AZD7798 Safety, Tolerability, and Pharmacokinetics After a Single Ascending and Repeat Dose Administrations to Healthy Subjects, and Patients With Crohn's Disease
CompletedNCT05452304
Start: 2022-07-12End: 2024-11-27Updated: 2025-12-03
Positron Emission Tomography (PET) Study of Changes in [11C]AZ14132516 Uptake Following Administration of AZD7798 to Healthy Participants and Patients With Crohn's Disease
CompletedNCT06053424
Start: 2023-09-25End: 2024-10-08Updated: 2025-08-27
Positron Emission Tomography Study of Changes in [11C]AZ14132516 Uptake Following Administration of AZD7798 to Patients With Crohn's Disease.
CompletedNCT06432764
Start: 2024-10-16End: 2026-03-27Updated: 2026-04-14
Phase 2
Phase IIa Study Evaluating AZD7798 in Crohn's Disease
Active, not recruitingNCT06450197
Start: 2024-08-28End: 2027-05-14Updated: 2026-09-18
A Double-blind, Placebo-controlled Phase IIa Study to Evaluate the Efficacy and Safety of AZD7798 in Patients with Moderate to Severe Crohn’s Disease (AMALTHEA)
RecruitingCTIS2023-510487-12-00
Start: 2024-11-29Target: 77Updated: 2026-01-22
A Participant- and Investigator-blind, Randomised, Placebo controlled Phase II Study to Evaluate Safety, Tolerability, and Mucosal Repair with AZD7798 in Patients with Active Ileal Crohn’s Disease and an Ileostomy (CALLISTO)
RecruitingCTIS2024-514407-33-00
Start: 2024-12-10Target: 27Updated: 2025-09-26
Study Evaluating AZD7798 for Treatment in Crohn's Disease Patients With an Ileostomy
Active, not recruitingNCT06681324
Start: 2024-12-11End: 2027-09-03Updated: 2026-08-27